What Is the Difference Between FDA Clearance and FDA Approval for AI Tools?

Two Different Regulatory Pathways, Not Interchangeable Terms

“FDA clearance” and “FDA approval” are often used loosely and interchangeably in casual conversation, but within the FDA’s actual regulatory framework, they refer to distinct pathways with different evidentiary standards and requirements. In general terms, clearance is commonly associated with a pathway where a manufacturer demonstrates that a new device is substantially similar to an already legally marketed device with a similar intended use, while approval pathways are generally associated with a more extensive review process, often applied to higher-risk devices where more comprehensive evidence of safety and effectiveness is required. Which pathway a given device goes through is determined primarily by its risk classification and specific intended use, following the FDA’s broader risk-based approach to medical device regulation.

Because these terms carry specific, technical meanings within FDA’s regulatory system, using them precisely — and understanding that a product description might legitimately use one term rather than the other for a specific, technical reason — helps avoid overstating or understating what a given regulatory pathway actually involved.

Why AI Tools Can Go Through Either Pathway

Just as with medical devices generally, AI-powered medical devices are not confined to a single regulatory pathway. An AI tool intended for a use case similar to an already-authorized device, and posing a comparable level of risk, may go through a clearance-type pathway. An AI tool intended for a more novel, higher-risk use case may require a more extensive approval-type process involving more substantial supporting evidence. This means it’s not accurate to assume all AI medical devices are treated identically from a regulatory standpoint — the specific pathway depends on the nature and risk profile of each individual product, not on the general category of “AI-powered” alone.

Additional Considerations Specific to AI-Based Tools

Beyond the standard clearance-versus-approval distinction, the FDA has been developing specific guidance and regulatory considerations relevant to characteristics that can be somewhat unique to AI and machine learning-based medical devices, such as how a device might be updated over time or, in some cases, continue to learn and adapt after its initial authorization. These considerations reflect an evolving effort to apply the agency’s broader device regulatory principles to technology that can behave differently from more traditional, static medical devices, and this remains an area of ongoing regulatory development.

Bottom Line

FDA clearance and FDA approval are distinct regulatory pathways with different evidentiary requirements, generally determined by a device’s risk classification and intended use rather than by whether it involves AI — AI-powered medical devices can go through either pathway depending on their specific risk profile, and neither term should be treated as automatically implying greater rigor than the other outside its specific regulatory context.